High volume hemodiafiltration in chronic hemodialysis patients: value of β2 microglobulin clearance in the quality control of the procedure
Abstract
Introduction: On line high volume hemodiafiltration (HVHDF) has shown to improve the clearance of medium molecules in dialyzed patients through high volumes of convection. Objective: The objective of this work is to evaluate the effectiveness of this technique in β2 microglobulin depuration, comparing its basal concentration, in chronic hemodialyzed patients, with the final concentration of the analyzed period. Further more, the KDQOL-SF was performed in order to evaluate the quality of life of the patients who participated in the study. Methods: Longitudinal cohort study of prevalent patients in highflux hemodialysis who were changed to on line high volume hemodiafiltration. Among other, β2 microglobulin clearance and its concentrations changes over time were measured as indicators of efficiency and adequacy of treatment. A statistical package Stata 11 was used. Results: Total follow up period was of 84 months (average 23,4 ± 19 months per patient). 8978 treatments were performed. Basal levels of β2 were; 36.05 mg/l ± 10, when admitted and 31.2 ± 10 (p=0.03), at the end of the study. Clearance mean of β2 was of 71 ± 16ml/min. The levels of β2 at the beginning of the study were associated with elapsed time from the first dialysis of the patients (r 0.4 – p< 0,02). Five years of conventional hemodialysis increase 11.2 mg/l the levels of β2 seric microglobulin and to obtain levels below 30 mg/l in 50% of our patients, 5 years of High Volume HDF is required. Conclusion: Values of β2 basal microglobulin in patients with chronic renal failure undergoing dialysis, are related to the time spent under hemodialysis treatment. In these patients, levels of seric β2 microglobulin, decrease slowly and progressively and reach clinical significance when the technique is high volume hemodiafiltration.
References
Levin A, Foley RN. Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis. 2000;36(6 Suppl 3):S24-30.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis. 1996;28(1):53-61.
Grupo de Trabajo de Anemia, Sociedad Argentina de Nefrología; Consejo de Anemia, Asociación Nefrológica de Buenos Aires. Guías para el manejo de la anemia en la Enfermedad Renal Crónica. Buenos Aires; 2013.
Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012;(Supl 2):279-335.
Sistema Nacional de Información de Procuración y Trasplante de la República Argentina. Registro Nacional de Insuficiencia Renal Crónica Terminal. Buenos Aires: INCUCAI; 2012.
Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Haemoglobin levels variability: Association with comorbidity intercurrent events, and hospitalization. Clin J Am Soc Nephrol. 2006;1(6):1205-10.
Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;47(1):186-92.
Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, et al. Left ventricular mass index increase in early renal disease impact of decline in hemoglobina. Am J Kidney Dis. 1999;34(1):125-35.
Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients. J Am Soc Nephrol. 1996;7(12):2654-7.